My research focuses on membrane transporter-mediated drug disposition and toxicity, with particular emphasis on OAT1's role in tenofovir-induced nephrotoxicity. I have investigated LAT1- and OAT-mediated uptake of the PET probe [¹⁸F]FAMT in tumors and kidneys, as well as the inhibitory kinetics of canagliflozin on SGLT2. Recently, I have turned to natural product-based interventions, such as apigenin, to mitigate drug-induced renal injury. My broader interests include the pharmacokinetics of imaging probes and the integration of natural compounds into transporter-targeted therapy.